Outlook Therapeutics, Inc. (OTLK) stock
OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
$0.36−0.04 (-8.94%)
Close on Nov 17, 2026Market cap $87.79MP/E –Yield –
Outlook Therapeutics enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Outlook Therapeutics's enterprise value was $78.75M on Nov 11, 2026, against $88.38M a year earlier. Over the last 5 years it ranged from $4.61M to $402.97M, with a median of $103.32M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $78.75M | +2.2% |
| 2025 | Dec 31, 2025 | $77.06M | +154.7% |
| 2024 | Dec 31, 2024 | $30.25M | -61.8% |
| 2023 | Dec 29, 2023 | $79.15M | -65.3% |
| 2022 | Dec 30, 2022 | $228.10M | +1.1% |
| 2021 | Dec 31, 2021 | $225.51M | +47.6% |
| 2020 | Dec 31, 2020 | $152.80M | -85.9% |
| 2019 | Dec 31, 2019 | $1.09B | +3040.6% |
| 2018 | Dec 31, 2018 | $34.56M | +17.4% |
| 2017 | Dec 29, 2017 | $29.43M | -57.4% |
| 2016 | Dec 30, 2016 | $69.10M | – |
See a number that looks wrong?